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 Abstract 
 Background: Greater understanding of differences in baseline impairment and disease pro-
gression in patients with Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD) 
may improve the interpretation of drug effects and the design of future studies.  Methods: 
This was a retrospective analysis of three randomized, double-blind rivastigmine databases 
(one in PDD, two in AD). Impairment on the Alzheimer’s Disease Assessment Scale–cognitive 
subscale (ADAS-cog), Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS-
ADL) scale, 10-item Neuropsychiatric Inventory (NPI-10) and the ADCS–Clinical Global Im-
pression of Change (CGIC) was compared [standardized difference (Cohen’s d), similar if <0.1]. 
 Results: Patients with AD or PDD had similar levels of impairment on the ADAS-cog and NPI-
10. Scores on the ADCS-ADL scale (standardized difference = 0.47) and the ADAS-cog mem-
ory domain (total, 0.33; items, 0.10–0.58) were higher in AD; PDD patients were more impaired 
in the language (0.23) and praxis (0.34) domains. AD patients receiving placebo showed great-
er deterioration on the ADAS-cog (0.14) and improvement on the NPI-10 (0.11) compared with 
patients with PDD.  Conclusion: Differing patterns of impairment occur in AD and PDD. 
 © 2013 S. Karger AG, Basel 
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 Introduction 
 Alzheimer’s disease (AD) is a chronic, neurodegenerative disorder, a principle manifes-
tation of which is loss of cholinergic transmission in the central nervous system  [1] . Clinically, 
AD presents as progressive impairment in cognition, behavior and the patient’s ability to 
perform activities of daily living (ADL).
 A number of clinical trials have demonstrated that treatment with a cholinesterase in-
hibitor, such as rivastigmine, is associated with symptomatic improvements in cognition, 
behavior and the ability to perform ADL in patients with mild-to-moderate AD  [2–4] . 
Rivastigmine is approved (in both oral and transdermal formulations) for the symptomatic 
treatment of mild-to-moderate AD in the USA and a number of other countries worldwide, 
and rivastigmine patch for severe AD in the USA.
 Cholinergic system deficits are also pronounced in Parkinson’s disease (PD)  [5] and are 
believed to be associated with impaired cognitive function, leading to development of 
dementia in many patients with PD (Parkinson’s disease dementia, PDD), especially as 
PD-related pathology begins to involve neocortical areas  [6, 7] . Epidemiological studies have 
estimated that between 24 and 31% of patients with PD meet criteria for dementia  [8] . 
Rivastigmine has demonstrated efficacy in mild-to-moderate PDD  [9] and is approved for this 
indication in several countries, including the USA. 
 The Alzheimer’s Disease Assessment Scale (ADAS) was developed to evaluate the severity 
and progression of both cognitive and non-cognitive dysfunction in patients with AD  [10] . 
Validation of the cognitive subscale of the ADAS (ADAS-cog) has confirmed that the ADAS-cog 
can reliably assess increasing severity of dementia in patients with AD  [11] , and thus is now 
widely considered the gold standard measure of cognitive function in clinical drug trials of 
patients with mild-to-moderate AD. More recently, the use of the ADAS-cog in patients with 
PDD has also been validated  [12] . The ADAS-cog assesses patients on 11 items, which evaluate 
three primary symptom domains: language, memory and praxis  [13, 14] .
 Previous clinical studies of rivastigmine in AD and PDD provide a wealth of data pertaining 
to the use of rivastigmine in these patient populations  [2–4, 9, 15, 16] . More specifically, these 
databases contain large amounts of baseline and post-baseline ADAS-cog data, including indi-
vidual item and symptom domain scores. In addition to cognitive assessments, clinical trials 
of rivastigmine in AD and PDD have also assessed efficacy on a number of other scales, 
including the Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS-ADL) 
scale  [2, 9, 17] , the 10-item Neuropsychiatric Inventory (NPI-10)  [2, 9, 18] and the Alzheimer’s 
Disease Cooperative Study–Clinical Global Impression of Change (ADCS-CGIC)  [2–4, 9, 15, 16, 
19] . Due to the large numbers of patients included in these databases, comparative analysis 
of the severity of baseline impairment on these measures across these trial populations may 
further elucidate disease-specific differences in patterns of impairment in these patients.
 In a previous study, significantly different cognitive profiles were reported between care-
fully matched subjects with PDD and AD (n = 488 in each group)  [20] . These groups differed 
significantly on all measures, except for the ADAS-cog item naming objects/fingers. Based on 
standardized Z-scores, the groups were shown to differ most in the categories attention and 
calculation taken from the Mini-Mental State Examination (MMSE; serial 7s subtraction task), 
followed by the ADAS-cog items orientation, praxis and following commands  [20] .
 The aim of this retrospective,  post hoc  analysis was to use available clinical data  [2–4, 9, 
15, 16] to investigate whether there are differences in the range of impairments observed at 
baseline and the rates of change in these domains over time in AD and PDD patients. Baseline 
scores on the total ADAS-cog, total ADCS-ADL, total NPI-10, the ADAS-cog’s symptom domains 
(language, memory and praxis), and the 11 individual ADAS-cog items were compared 
between the AD and PDD patient populations. Besides investigating baseline impairment, 
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calculating the change from baseline to the study endpoint in the placebo groups provided 
longitudinal data on disease progression over time in untreated patients with AD or PDD. 
Deterioration in cognition (ADAS-cog), behavior (NPI-10), ADL (ADCS-ADL) and global 
function (ADCS-CGIC) was compared between patients with AD or PDD randomized to receive 
placebo in these controlled clinical studies. Data were provided by a much larger set of AD 
patients than have been considered in previous analyses.
 Materials and Methods 
 Clinical Studies 
 A retrospective, exploratory analysis was conducted of three trial databases, namely 
(a) the Investigation of transDermal Exelon in ALzheimer’s disease (IDEAL) trial, 
CENA713D2320; (b) the EXelon in PaRkinson’s disEaSe dementia Study (EXPRESS), 
CENA713B2311, and (c) the Alzheimer's Disease with ENA 713 (ADENA) databases. The 
full details of these trial databases have been published previously  [2–4, 9, 15, 16] . Each of 
these studies was conducted according to the ethical principles of the Declaration of 
Helsinki.
 Briefly, IDEAL was an international, 24-week, double-blind, placebo- and active-controlled 
trial designed to investigate the efficacy and safety of rivastigmine (patch and capsules) 
versus placebo in mild-to-moderate AD  [2] . Eligible patients had a diagnosis of dementia of 
the Alzheimer’s type  [21, 22] and probable AD of mild-to-moderate severity (MMSE score of 
10–20, inclusive)  [23] . Patients were randomized to receive a rivastigmine patch (9.5 or 17.4 
mg/24 h), rivastigmine capsules (12 mg/day) or placebo. Primary outcomes were the change 
from baseline at week 24 on the ADAS-cog and ADCS-CGIC. The ADCS-ADL and NPI were 
secondary outcomes. 
 EXPRESS was an international, 24-week, double-blind, placebo-controlled trial of 
rivastigmine in PDD  [9] . Patients had a diagnosis of probable PD (UK Parkinson’s Disease 
Society Brain Bank Clinical Criteria) and mild-to-moderately severe dementia (DSM-IV 
criteria;  MMSE score of 10–24, inclusive). Study participants were randomized in a 2: 1 ratio 
to receive rivastigmine capsules (3–12 mg/day) or placebo. Primary outcomes were the 
ADCS-CGIC and the change from baseline at week 24 on the ADAS-cog. The change from 
baseline at week 24 on the ADCS-ADL and NPI-10 were secondary outcome measures.
 The ADENA program was a retrospective analysis of four 26-week, randomized, double-
blind, placebo-controlled trials of rivastigmine capsules in patients with mild-to-moderate 
AD  [3, 4, 15, 16] . In all four trials, patients had been diagnosed with dementia of the Alzheimer’s 
type (DSM-IV, NINCDS/ADRDA criteria)  [21, 22] and probable AD of mild-to-moderate 
severity (MMSE scores of 10–26, inclusive)  [23] . Patients were randomized to receive either 
rivastigmine capsules or placebo. Two studies evaluated rivastigmine 1–4 and 6–12 mg/day, 
one evaluated rivastigmine 2–12 mg/day twice daily and thrice daily and the fourth evaluated 
rivastigmine 3, 6 and 9 mg/day. Outcome measures in each of these studies included the 
change from baseline at week 26 on the ADAS-cog and the Clinician Interview–Based 
Impression of Change incorporating caregiver information (CIBIC-plus).
 Statistical Analysis 
 In the current analysis, baseline ADAS-cog total and domain scores from the IDEAL and 
ADENA trial databases provided data on AD patients, and EXPRESS provided data on PDD 
patients. ADCS-ADL and NPI-10 data were available from the IDEAL and EXPRESS databases; 
however, these scales were not outcome measures in the ADENA program. ADCS-CGIC data 
were available from the IDEAL and EXPRESS patient populations, and CIBIC-plus data from 
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ADENA were also included in the analysis. For each outcome measure, all patients who 
completed a baseline assessment were also included in the analyses. ADCS-CGIC scores and 
the mean change from baseline at week 24/26 on the ADCS-ADL, NPI-10 and ADAS-cog total 
and domain scores were calculated for the placebo group (intent-to-treat population).
 The mean baseline score on the ADAS-cog, NPI-10 scale and ADCS-ADL scale and the 
standard deviation (SD) from the mean were calculated in the AD and PDD patients using an 
analysis of covariance (ANCOVA) model with study as a factor and baseline score as a covariate. 
The mean (SD) change from baseline at the study endpoint on each of the outcome measures 
was calculated using two ANCOVA models: model 1 included study as a factor and baseline 
score as a covariate (where appropriate), and model 2 included study as a factor and baseline 
MMSE score and corresponding baseline score as covariates (where appropriate). Stan-
dardized differences (Cohen’s d) were calculated to compare baseline and change-from-
baseline (where applicable) NPI-10, ADCS-ADL, ADCS-CGIC and ADAS-cog total, domain and 
item scores between the AD and PDD patient populations. Scores on each outcome measure 
were considered to be similar in the AD and PDD population, if the calculated standardized 
difference was below the applied threshold of 0.1.
 Results 
 Patients 
 In total, baseline data were provided by 3,999 AD patients (from the ADENA and IDEAL 
databases) and 541 PDD patients (EXPRESS database). Baseline demographics and patient 
characteristics are summarized in  table 1 . The AD and PDD patient populations were com-
parable in terms of age. However, the AD and PDD patient populations were significantly 
different in terms of gender, ethnic origin and their baseline MMSE score. The PDD popu-
lation was predominantly male (64.88%), while the AD population was predominantly 
female (61.09%). Overall, 99.63% of the PDD population and 89.02% of the AD population 
were Caucasian. The PDD population tended to show a higher mean score at baseline on the 
MMSE than the AD population ( table 1 ).
Table 1.  Baseline demographics and patient characteristics from the AD (ADENA and IDEAL) and PDD 
(EXPRESS) trial databases (randomized population)
AD (ADENA and IDEAL) 
(N = 3,999)
PDD (EXPRESS) 
(N = 541)
p value
Mean age ± SD, years 73.2 ± 8.04 72.7 ± 6.61 0.1432
Male:female, % 38.91:61.09 64.88:35.12 <0.0001*
Ethnic origin, %
Caucasian
Black
Oriental
Other
89.02
2.68
2.95
5.35
99.63
0.00
0.00
0.37
<0.0001*
MMSE score
Patients, n
Mean ± SD
3,987
18.7 ± 4.36
541
19.3 ± 3.91 0.0007
 * Where indicated, the p values were estimated using the χ2 test. All other p values derived from a 
two-sample t test.
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 Comparison of Baseline ADAS-cog, ADCS-ADL and NPI-10 Data between the AD and PDD 
Patient Populations 
 The mean total baseline ADAS-cog score differed by one point between the AD and PDD 
populations, with AD patients showing a higher mean score. However, the calculated stan-
dardized difference of 0.09 falls below the applied threshold of 0.1, suggesting that, overall, 
patients with PDD and AD had similar levels of cognitive impairment at baseline. The mean 
(SD) baseline ADCS-ADL scores were higher in the AD population than in the PDD population 
[AD: 49.25 (15.93), N = 1,104; PDD: 41.46 (18.31), N = 498; standardized difference = 0.47]. 
In the PDD population, a significant correlation was observed between the baseline ADCS-ADL 
score and the baseline score on the Unified Parkinson’s Disease Rating Scale Part V (r = –0.40; 
p < 0.0001), with the most severely affected patients showing the greatest impairment of ADL. 
Despite a trend towards higher baseline scores on the NPI-10 in patients with PDD compared 
with  AD [PDD: 12.83 (12.16), N = 500; AD: 12.03 (12.16), N = 1,103], the standardized 
difference of 0.07 suggests that, overall, behavioral disturbances manifested in similar levels 
in both the AD and PDD patients.
 When considering the three domains of the ADAS-cog (language, memory and praxis), 
patients with AD showed greater baseline impairment on the ADAS-cog memory domain than 
patients with PDD (standardized difference = 0.33;  fig. 1 ). In contrast, PDD patients were 
more impaired than the AD patients on the language and praxis ADAS-cog domains (stan-
dardized difference = 0.23 and 0.34, respectively;  fig. 1 ).  AD patients were more impaired 
than PDD patients on all of the individual items (word recognition, naming objects/fingers, 
orientation, word recall and remembering test instructions) that comprise the ADAS-cog 
memory domain ( fig. 2 ; standardized difference = 0.10–0.58).
 However, PDD patients showed greater impairment than AD patients on all items that 
comprise the ADAS-cog language domain (standardized difference = 0.14–0.39), except for 
word-finding difficulty (standardized difference = 0.04), and both items that comprise the 
ADAS-cog praxis domain (constructional praxis, standardized difference = 0.34 and 
ideational praxis, standardized difference = 0.27;  fig. 2 ). Overall, the greatest difference in 
the severity of cognitive impairment between AD and PDD patients was seen on the orien-
tation item, which forms part of the memory domain. Here, AD patients showed greater 
baseline impairment than PDD patients (standardized difference = 0.58). 
N = 3,983 3,969 3,971536 525 520
 Fig. 1. Baseline scores on the 
ADAS-cog symptom domains of 
language, memory and praxis for 
the AD (IDEAL and ADENA) and 
PDD (EXPRESS) patient popula-
tions (randomized population). 
Values represent calculated stan-
dardized differences comparing 
the AD and PDD patient popula-
tions. Error bars represent the SD 
from the mean. Standardized dif-
ferences were calculated using an 
ANCOVA model with study as a 
factor and corresponding base-
line score as a covariate (where 
appropriate). Higher scores re-
flect a greater impairment. 
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 ADCS-CGIC Scores and the Change from Baseline at Week 24/26 on the ADAS-cog,
ADCS-ADL and NPI-10 Scales in Patients with AD and PDD Receiving Placebo 
 Patients with AD in the placebo group showed a greater mean change from baseline at week 
24/26 than patients with PDD on the total ADAS-cog (standardized difference = 0.14 AD vs. 
PDD;  fig. 3 a). Similar findings were observed when including disease severity (baseline MMSE 
score) as a covariate in the ANCOVA model used to compare the AD and PDD patient popula-
tions (standardized difference = 0.16 AD vs.  PDD). No differences were seen between the patient 
populations on the ADCS-CGIC, irrespective of the baseline MMSE score [standardized differ -
ence = 0.09 (model 1) and 0.08 (model 2) AD vs. PDD;  fig. 3 b]. Irrespective of baseline disease 
severity (MMSE), greater decline from baseline to week 24 was observed on the NPI-10 in 
patients with PDD compared with those with AD [standardized difference = 0.11 (model 1) and 
0.29 (model 2) AD vs. PDD;  fig. 3 c]. A trend towards greater worsening was observed on the 
ADCS-ADL amongst patients with PDD compared with those with AD [standardized differ-
ence = 0.08 AD vs. PDD (model 1);  fig. 3 d]. When taking into account baseline disease severity, 
patients with PDD randomized to receive placebo showed a greater mean change from baseline 
at the study endpoint than patients with AD (standardized difference = 0.35 AD vs. PDD).
 Patients with AD randomized to receive placebo showed a greater mean (SD) change 
from baseline at week 24/26 than PDD patients who received placebo on the ADAS-cog 
memory domain [1.3 (4.20) and 0.3 (4.90) for AD (n = 1,148) and PDD (n = 158), respectively; 
standardized difference = 0.25 (model 1) and 0.34 (model 2) AD vs. PDD]. A greater mean 
change from baseline at the study endpoint on the ADAS-cog praxis domain was also observed 
N = 3,983 3,983 3,983 3,983 3,970 3,983 3,982 3,974 3,975 3,976 3,975537 538 538 537 526 539 539 534 535 525 528
 Fig. 2. Baseline scores on the individual ADAS-cog items that comprise the symptom domains of language, 
memory and praxis for the AD (IDEAL and ADENA) and PDD (EXPRESS) patient populations (randomized 
population). Values represent the calculated standardized differences comparing the AD and PDD patient 
populations. Error bars represent the SD from the mean. Standardized differences were calculated using an 
ANCOVA model with study as a factor and corresponding baseline score as a covariate (where appropriate). 
Higher scores reflect a greater impairment. 
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in patients with AD compared with patients with PDD. However, the observed difference was 
not maintained when baseline MMSE was included as a covariate in the model used to compare 
the AD and PDD patient populations [mean (SD) = 0.3 (1.48) and 0.1 (1.83) for AD (n = 1,148) 
and PDD (n = 152), respectively; standardized difference = 0.14 (model 1) and 0.00 (model 
2) AD vs. PDD, respectively]. A trend towards a greater change from baseline in the ADAS-cog 
language domain was observed in patients with AD compared with patients with PDD [0.6 
(2.63) and 0.4 (3.05) for AD (n = 1,152) and PDD (n = 161), respectively]. However, the calcu-
lated standardized difference falls below the applied threshold of 0.1 [standardized differ-
ence = 0.07 (model 1) and 0.00 (model 2) AD  vs.  PDD].
 Discussion 
 Despite cognitive deficits in both AD and PDD being related to cholinergic deficiency, 
mounting evidence suggests that these dementias are clinically and biologically distinct 
entities. PDD is commonly associated with α-synuclein (Lewy body) pathology, while AD is 
associated with neuritic plaques and neurofibrillary tangles in the basal forebrain  [7, 24] . 
Although there is a clear overlap in the clinical presentation of both diseases, there are also 
distinct differences. PD is typically classified as a movement disorder; however, there are also 
 Fig. 3. Mean change from baseline at week 24/26 on ADAS-cog ( a ), mean ADCS-CGIC score at week 24/26 
( b ), mean change from baseline at week 24 on NPI-10 ( c ), and mean change from baseline at week 24 on 
ADCS-ADL (intent-to-treat population) ( d ). Standardized differences (Cohen’s d) were calculated to compare 
the ADCS-CGIC score and the change in ADAS-cog, NPI-10 and ADCS-ADL score between the AD and PDD pa-
tient populations.  * ANCOVA model with study as a factor and corresponding baseline score as a covariate 
(where appropriate);  † ANCOVA model with study as a factor and baseline MMSE score and corresponding 
baseline score as covariates (where appropriate). ADAS-cog and ADCS-CGIC data were outcome measures in 
IDEAL, ADENA and EXPRESS. ADCS-ADL and NPI-10 were outcome measures in IDEAL and EXPRESS only. 
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non-motor features, including cognitive impairment  [25] . Research has suggested that brain 
cholinergic deficiencies may be greater in PDD than in mild AD  [26] . Patients with PDD 
predominantly show deficits in attention, executive function and visual spatial function  [27, 
28] . Memory impairment, which is dominant in AD, is less prominent in PDD  [29] . The 
predominant language abnormality in PDD is impairment of verbal fluency, which is more 
marked in PDD compared with AD  [7, 30] . Naming difficulties and impaired comprehension 
are also observed in PDD, although to a lesser extent than in patients with AD  [7, 31] . Neuro-
psychiatric symptoms are common in both AD and PDD  [28, 32] . Visual hallucinations, 
although present in both AD and PDD, tend to arise more commonly in PDD than in AD  [33] .
 In the current analysis, we compared baseline impairment in patients with AD and PDD 
on a range of outcome measures, namely the ADAS-cog, ADCS-ADL and NPI-10. These data 
suggest that patients with AD demonstrate greater impairment in memory than patients with 
PDD, while patients with PDD tended to show greater impairment in language (except word-
finding difficulty) and praxis. Overall, the greatest difference between patients with AD and 
PDD was observed on the orientation (memory) item. This observation is consistent with a 
previous analysis published by Bronnick et al.  [20] . Given the impact of PD on motor function, 
the observed greater impairment of praxis in PDD compared with AD was not unexpected. 
Bronnick et al.  [20]  also reported greater impairment of praxis in patients with PDD. However, 
they also noted that this might be difficult to interpret given the impact of motor disability on 
a patient’s ability to perform tasks, a point important to consider when interpreting the 
results of the current analysis. 
 Previous analyses have reported significant differences between patients with AD and 
PDD on the commands, constructional praxis, ideational praxis, word recall, word recognition 
and orientation items of the ADAS-cog, and the serial 7s subtraction task from the MMSE  [20] . 
Based on the Z-scores, the groups differed most on attention and calculation (assessed using 
the MMSE), followed by orientation  [20] . A direct logistic regression analysis showed that 
these variables reliably distinguished patients with AD and PDD with an overall success rate 
of 74.7%  [20] .
 In these studies, patients with AD were found to score higher on the ADCS-ADL scale at 
baseline than patients with PDD, suggesting that patients with PDD are more impaired in 
their ability to perform ADL. This is not unexpected, as PD is a complex movement disorder, 
in which symptoms such as rigidity, bradykinesia and tremor can compound cognitive deficits 
to further restrict a patient’s ability to perform tasks. Behavioral disturbances, as assessed 
using the NPI-10, appeared to manifest at similar levels in the two patient populations. 
However, stable doses of psychotropic medications were permitted at baseline in IDEAL and 
EXPRESS, and limited use of select medications in the ADENA program that may have masked 
behavioral disturbances in these patients. 
 Deterioration in global function, cognition, ADL and behavior was calculated for patients 
with AD and PDD randomized to receive placebo in these studies, allowing a comparison of 
disease progression over time in untreated AD and PDD patient populations. Overall, patients 
with AD showed greater deterioration in cognition (particularly memory) and fewer behav-
ioral symptoms compared with patients with PDD, but similar levels of decline in ADL and 
global function were seen for both patient groups. This trend (for cognition and ADL) is 
consistent with previous studies of rivastigmine in these patient populations  [28] . Further 
analyses taking into account the baseline MMSE score supported these findings, with the 
exception of the ADCS-ADL scale, where patients with PDD showed a greater mean change 
from baseline to the study endpoint than patients with AD. This suggests disease severity has 
a greater impact on deterioration of the ability to perform ADL in patients with PDD compared 
with AD. These data suggest that despite there being a common cholinergic basis to these 
diseases, they are distinctly different in aspects of their clinical features and progression. 
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Cognitive decline may be slower in PDD although this could be influenced by the range of 
cognitive domains assessed in these studies, since the ADAS-cog was originally developed to 
monitor progression in AD. As such, the scales employed may not fully quantify specific 
cognitive and functional impairments in the PDD patient population. 
 This was a retrospective, hypothesis-forming, exploratory analysis of baseline and 
follow-up data collected during the IDEAL study, ADENA program and EXPRESS. Data on AD 
and PDD patients were derived from three independent trial databases, which were not 
prospectively powered to detect differences in baseline characteristics or longitudinal differ-
ences between the patient populations. As a result, the data should be interpreted with 
caution. Larger studies enrolling both AD and PDD patients would be required to fully inves-
tigate and compare the range of impairments observed in these populations. 
 The findings of the current analyses demonstrate differing patterns of impairment 
between patients with AD and PDD, despite both illnesses involving cholinergic deficiencies. 
The results support previous suggestions that the dementia associated with PD is not simply 
AD comorbid to PD. Greater understanding of the clinical features and the progression of 
these disease states will be valuable in improving the accuracy of diagnosis and appropriate 
management of these conditions. 
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